Firmagon
Term · Oncology and biomedicine · MLC-T-ONC-003223
A drug used to treat advanced prostate cancer. Firmagon binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the testicles to stop making testosterone. Firmagon may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called degarelix acetate.
| Identifier | MLC-T-ONC-003223 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | degarelix acetate |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003223",
"term": "Firmagon",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat advanced prostate cancer. Firmagon binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the testicles to stop making testosterone. Firmagon may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called degarelix acetate.",
"synonyms": [
"degarelix acetate"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/firmagon/"
}
Record 7,320 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.